APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Meningococcal Group A and C Conjugate Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Meningococcal Group A and C Conjugate Vaccine Market Outlook and Growth Opportunities 2026

Report ID 174011990429 December 2025194 pages

Choose your research edition.

Industry ResearchMeningococcal Group A and C Conjugate Vaccine Industry Research Report 2026105 pages · $2,950 USDIndustry Growth & TrendsGlobal Meningococcal Group A and C Conjugate Vaccine Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal Meningococcal Group A and C Conjugate Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Meningococcal Group A and C Conjugate Vaccine Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Meningococcal Group A and C Conjugate Vaccine Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Meningococcal Group A and C Conjugate Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Meningococcal Group A and C Conjugate Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Meningococcal Group A and C Conjugate Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Meningococcal Group A and C Conjugate Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Meningococcal Group A and C Conjugate Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Meningococcal Group A and C Conjugate Vaccine market include GSK, Pfizer, Sanofi Pasteur and Chongqing Zhifei Biological Products, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Meningococcal Group A and C Conjugate Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Meningococcal Group A and C Conjugate Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Meningococcal Group A and C Conjugate Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Meningococcal Group A and C Conjugate Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Meningococcal Group A and C Conjugate Vaccine Segment by Company

GSK

Pfizer

Sanofi Pasteur

Chongqing Zhifei Biological Products

Meningococcal Group A and C Conjugate Vaccine Segment by Type

Prefilled

Non-prefilled

Meningococcal Group A and C Conjugate Vaccine Segment by Application

Adults

Children

Meningococcal Group A and C Conjugate Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Meningococcal Group A and C Conjugate Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Meningococcal Group A and C Conjugate Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Meningococcal Group A and C Conjugate Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Meningococcal Group A and C Conjugate Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Group A and C Conjugate Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Group A and C Conjugate Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Group A and C Conjugate Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Meningococcal Group A and C Conjugate Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Meningococcal Group A and C Conjugate Vaccine industry.

Chapter 3: Detailed analysis of Meningococcal Group A and C Conjugate Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Meningococcal Group A and C Conjugate Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Meningococcal Group A and C Conjugate Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Meningococcal Group A and C Conjugate Vaccine Industry Trends Table 2. Meningococcal Group A and C Conjugate Vaccine Industry Drivers Table 3. Meningococcal Group A and C Conjugate Vaccine Industry Opportunities and Challenges Table 4. Meningococcal Group A and C Conjugate Vaccine Industry Restraints Table 5. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Meningococcal Group A and C Conjugate Vaccine Revenue Share by Company (2021-2026) Table 7. Global Meningococcal Group A and C Conjugate Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Meningococcal Group A and C Conjugate Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Meningococcal Group A and C Conjugate Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Meningococcal Group A and C Conjugate Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Meningococcal Group A and C Conjugate Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Meningococcal Group A and C Conjugate Vaccine Company, Product Type & Application Table 13. Global Meningococcal Group A and C Conjugate Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Meningococcal Group A and C Conjugate Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Prefilled Table 18. Significant Companies of Non-prefilled Table 19. Global Meningococcal Group A and C Conjugate Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Meningococcal Group A and C Conjugate Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Meningococcal Group A and C Conjugate Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Meningococcal Group A and C Conjugate Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Meningococcal Group A and C Conjugate Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Adults Table 30. Significant Companies of Children Table 31. Global Meningococcal Group A and C Conjugate Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Meningococcal Group A and C Conjugate Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Meningococcal Group A and C Conjugate Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Meningococcal Group A and C Conjugate Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Meningococcal Group A and C Conjugate Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Meningococcal Group A and C Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Meningococcal Group A and C Conjugate Vaccine Sales by Region (2021-2026) & (K Units) Table 43. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Meningococcal Group A and C Conjugate Vaccine Sales by Region (2027-2032) & (K Units) Table 45. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Meningococcal Group A and C Conjugate Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Meningococcal Group A and C Conjugate Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Meningococcal Group A and C Conjugate Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Meningococcal Group A and C Conjugate Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 56. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Meningococcal Group A and C Conjugate Vaccine Sales by Country (2027-2032) & (K Units) Table 58. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Meningococcal Group A and C Conjugate Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Meningococcal Group A and C Conjugate Vaccine Sales Value Market Share by Country (2027-2032) Table 63. GSK Company Information Table 64. GSK Business Overview Table 65. GSK Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. GSK Meningococcal Group A and C Conjugate Vaccine Product Portfolio Table 67. GSK Recent Development Table 68. Pfizer Company Information Table 69. Pfizer Business Overview Table 70. Pfizer Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Pfizer Meningococcal Group A and C Conjugate Vaccine Product Portfolio Table 72. Pfizer Recent Development Table 73. Sanofi Pasteur Company Information Table 74. Sanofi Pasteur Business Overview Table 75. Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Product Portfolio Table 77. Sanofi Pasteur Recent Development Table 78. Chongqing Zhifei Biological Products Company Information Table 79. Chongqing Zhifei Biological Products Business Overview Table 80. Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Product Portfolio Table 82. Chongqing Zhifei Biological Products Recent Development Table 83. Key Raw Materials Table 84. Raw Materials Key Suppliers Table 85. Meningococcal Group A and C Conjugate Vaccine Distributors List Table 86. Meningococcal Group A and C Conjugate Vaccine Customers List Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Meningococcal Group A and C Conjugate Vaccine Product Image Figure 2. Global Meningococcal Group A and C Conjugate Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Meningococcal Group A and C Conjugate Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Meningococcal Group A and C Conjugate Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Meningococcal Group A and C Conjugate Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Meningococcal Group A and C Conjugate Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Prefilled Image Figure 10. Non-prefilled Image Figure 11. Global Meningococcal Group A and C Conjugate Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Meningococcal Group A and C Conjugate Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Meningococcal Group A and C Conjugate Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Meningococcal Group A and C Conjugate Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type (2021-2032) Figure 17. Adults Image Figure 18. Children Image Figure 19. Global Meningococcal Group A and C Conjugate Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Meningococcal Group A and C Conjugate Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Meningococcal Group A and C Conjugate Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Meningococcal Group A and C Conjugate Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Meningococcal Group A and C Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Meningococcal Group A and C Conjugate Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Meningococcal Group A and C Conjugate Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Meningococcal Group A and C Conjugate Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Meningococcal Group A and C Conjugate Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Meningococcal Group A and C Conjugate Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Meningococcal Group A and C Conjugate Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Prefilled
  • Non-prefilled
Applications
  • Adults
  • Children
Companies covered
  • GSK
  • Pfizer
  • Sanofi Pasteur
  • Chongqing Zhifei Biological Products

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Meningococcal Group A and C Conjugate Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Meningococcal Group A and C Conjugate Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Meningococcal Group A and C Conjugate Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Meningococcal Group A and C Conjugate Vaccine Market Dynamics
  1. 2.1 Meningococcal Group A and C Conjugate Vaccine Industry Trends
  2. 2.2 Meningococcal Group A and C Conjugate Vaccine Industry Drivers
  3. 2.3 Meningococcal Group A and C Conjugate Vaccine Industry Opportunities and Challenges
  4. 2.4 Meningococcal Group A and C Conjugate Vaccine Industry Restraints
3 Meningococcal Group A and C Conjugate Vaccine Market by Company
  1. 3.1 Global Meningococcal Group A and C Conjugate Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Meningococcal Group A and C Conjugate Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Meningococcal Group A and C Conjugate Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Meningococcal Group A and C Conjugate Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Meningococcal Group A and C Conjugate Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Meningococcal Group A and C Conjugate Vaccine Company Product Type and Application
  8. 3.8 Global Meningococcal Group A and C Conjugate Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Meningococcal Group A and C Conjugate Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Meningococcal Group A and C Conjugate Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Meningococcal Group A and C Conjugate Vaccine Market by Type
  1. 4.1 Meningococcal Group A and C Conjugate Vaccine Type Introduction
  2. 4.1.1 Prefilled
  3. 4.1.2 Non-prefilled
  4. 4.2 Global Meningococcal Group A and C Conjugate Vaccine Sales Volume by Type
  5. 4.2.1 Global Meningococcal Group A and C Conjugate Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Meningococcal Group A and C Conjugate Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Meningococcal Group A and C Conjugate Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Type
  9. 4.3.1 Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type (2021-2032)
5 Meningococcal Group A and C Conjugate Vaccine Market by Application
  1. 5.1 Meningococcal Group A and C Conjugate Vaccine Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Children
  4. 5.2 Global Meningococcal Group A and C Conjugate Vaccine Sales Volume by Application
  5. 5.2.1 Global Meningococcal Group A and C Conjugate Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Meningococcal Group A and C Conjugate Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Meningococcal Group A and C Conjugate Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Application
  9. 5.3.1 Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application (2021-2032)
6 Meningococcal Group A and C Conjugate Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Meningococcal Group A and C Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Meningococcal Group A and C Conjugate Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Meningococcal Group A and C Conjugate Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Meningococcal Group A and C Conjugate Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Meningococcal Group A and C Conjugate Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Meningococcal Group A and C Conjugate Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Meningococcal Group A and C Conjugate Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Meningococcal Group A and C Conjugate Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Country, 2025 VS 2032
7 Meningococcal Group A and C Conjugate Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Meningococcal Group A and C Conjugate Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Meningococcal Group A and C Conjugate Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Meningococcal Group A and C Conjugate Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Meningococcal Group A and C Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Meningococcal Group A and C Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Meningococcal Group A and C Conjugate Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Meningococcal Group A and C Conjugate Vaccine Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Meningococcal Group A and C Conjugate Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Meningococcal Group A and C Conjugate Vaccine Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 Sanofi Pasteur
  14. 8.3.1 Sanofi Pasteur Company Information
  15. 8.3.2 Sanofi Pasteur Business Overview
  16. 8.3.3 Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Product Portfolio
  18. 8.3.5 Sanofi Pasteur Recent Developments
  19. 8.4 Chongqing Zhifei Biological Products
  20. 8.4.1 Chongqing Zhifei Biological Products Company Information
  21. 8.4.2 Chongqing Zhifei Biological Products Business Overview
  22. 8.4.3 Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Product Portfolio
  24. 8.4.5 Chongqing Zhifei Biological Products Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Meningococcal Group A and C Conjugate Vaccine Value Chain Analysis
  2. 9.1.1 Meningococcal Group A and C Conjugate Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Meningococcal Group A and C Conjugate Vaccine Sales Mode & Process
  6. 9.2 Meningococcal Group A and C Conjugate Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Meningococcal Group A and C Conjugate Vaccine Distributors
  9. 9.2.3 Meningococcal Group A and C Conjugate Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst